Stacey Branyon
Family · Honea Path, SCNPI 1801837489
Payments from drug & device makers
Across 319 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$451
- Pfizer$403
- Lilly USA, LLC$375
- Amgen$257
- GSK$247
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,890100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 98 | $1,311 |
| Novo Nordisk | 32 | $451 |
| Pfizer | 29 | $403 |
| Lilly USA, LLC | 24 | $375 |
| Amgen | 16 | $257 |
| GSK | 9 | $247 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $213 |
| Boehringer Ingelheim | 12 | $197 |
| AstraZeneca | 13 | $187 |
| Otsuka America Pharmaceutical, Inc. | 9 | $186 |
| Novartis | 11 | $178 |
| Abbott | 10 | $155 |
| Esperion Therapeutics, Inc. | 8 | $138 |
| Exact Sciences | 6 | $95 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $78 |
| Dexcom, Inc. | 4 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Merck | 3 | $39 |
| Insmed, Inc. | 2 | $34 |
| Ultragenyx Pharmaceutical Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $16 |
| Genentech USA, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SHINGRIX$110
How this compares
$4,890 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $115,884 |
| LinzessLinaclotide | 79 | $67,829 |
| MounjaroTirzepatide | 49 | $55,436 |
| EliquisApixaban | 48 | $49,422 |
| Repatha SureclickEvolocumab | 48 | $42,677 |
| JardianceEmpagliflozin | 27 | $39,069 |
| MyrbetriqMirabegron | 39 | $31,975 |
| TrulicityDulaglutide | 18 | $28,697 |
| UbrelvyUbrogepant | 15 | $23,812 |
| JanuviaSitagliptin Phosphate | 20 | $18,402 |
| FarxigaDapagliflozin Propanediol | 19 | $16,554 |
| Spiriva RespimatTiotropium Bromide | 20 | $9,902 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,300 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,950 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $6,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $451 | $115,88494 claims |
| AbbVieLinzess, Ubrelvy | $1,311 | $91,64194 claims |
| Lilly USA, LLCMounjaro, Trulicity | $375 | $84,13367 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Synjardy Xr | $197 | $55,79559 claims |
| PfizerEliquis | $403 | $49,42248 claims |
| AstraZenecaFarxiga, Symbicort | $187 | $23,50442 claims |
| MerckJanuvia | $39 | $18,40220 claims |
| GSKTrelegy Ellipta | $247 | $9,30011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.
Other family in Honea Path
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.